Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGB-A3055 + tislelizumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BGB-A3055 + tislelizumab is a combination therapy currently under investigation for the treatment of advanced or metastatic solid tumors. **BGB-A3055** is a fully humanized, afucosylated monoclonal antibody targeting the chemokine receptor **CCR8**; it works by binding with high affinity to CCR8, blocking CCL1-CCR8 signaling, and efficiently depleting tumor-infiltrating regulatory T cells (Tregs) via antibody-dependent cellular cytotoxicity (ADCC). This depletion enhances anti-tumor immunity in the tumor microenvironment. **Tislelizumab** is a monoclonal antibody targeting **Programmed cell death protein 1 (PD-1)**, acting as an immune checkpoint inhibitor to restore anti-tumor immune responses. The combination aims to increase anti-tumor efficacy through complementary immune mechanisms. Both agents are administered intravenously. Development is led by BeiGene, and early clinical trials are focused on safety, dose finding, and preliminary anti-tumor efficacy[1][2][3][4][5].
- Other names
- BGB-A3055 + tislelizumab
02
Targets
CCR8PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BGB-A3055 + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGB-A3055 + tislelizumab.